Nektar Therapeutics (NASDAQ:NKTR) hit a new 52-week high on Tuesday . The company traded as high as $18.36 and last traded at $18.23, with a volume of 839,938 shares trading hands. The stock had previously closed at $17.83.

A number of equities research analysts have weighed in on NKTR shares. Zacks Investment Research lowered shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 2nd. Piper Jaffray Cos. reiterated a “buy” rating and set a $17.00 target price on shares of Nektar Therapeutics in a research note on Wednesday, May 4th. Finally, Brean Capital reiterated a “buy” rating on shares of Nektar Therapeutics in a research note on Wednesday, May 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $19.40.

The stock’s 50 day moving average price is $16.27 and its 200 day moving average price is $14.44. The firm’s market capitalization is $2.50 billion.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.03. During the same period last year, the business posted ($0.40) EPS. The business had revenue of $32.77 million for the quarter, compared to the consensus estimate of $34.17 million. The firm’s quarterly revenue was up 44.6% compared to the same quarter last year. On average, analysts forecast that Nektar Therapeutics will post ($1.11) earnings per share for the current year.

In other Nektar Therapeutics news, Director Robert Chess sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $14.10, for a total value of $70,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Jillian B. Thomsen sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $15.09, for a total transaction of $1,509,000.00. Following the completion of the sale, the chief accounting officer now owns 106,809 shares of the company’s stock, valued at $1,611,747.81. The disclosure for this sale can be found here.

Other large investors have recently made changes to their positions in the company. Principal Financial Group Inc. increased its stake in shares of Nektar Therapeutics by 4.9% in the fourth quarter. Principal Financial Group Inc. now owns 1,208,204 shares of the biopharmaceutical company’s stock valued at $20,359,000 after buying an additional 56,510 shares during the period. BlackRock Advisors LLC increased its stake in shares of Nektar Therapeutics by 2.0% in the fourth quarter. BlackRock Advisors LLC now owns 2,342,182 shares of the biopharmaceutical company’s stock valued at $39,466,000 after buying an additional 45,091 shares during the period. Finally, New York State Common Retirement Fund increased its stake in shares of Nektar Therapeutics by 1.9% in the fourth quarter. New York State Common Retirement Fund now owns 177,127 shares of the biopharmaceutical company’s stock valued at $2,985,000 after buying an additional 3,300 shares during the period.

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.